229 related articles for article (PubMed ID: 22153696)
1. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
Koh KK; Quon MJ; Shin KC; Lim S; Lee Y; Sakuma I; Lee K; Han SH; Shin EK
Atherosclerosis; 2012 Feb; 220(2):537-44. PubMed ID: 22153696
[TBL] [Abstract][Full Text] [Related]
2. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
Koh KK; Oh PC; Sakuma I; Lee Y; Han SH; Shin EK
Int J Cardiol; 2016 Oct; 221():342-6. PubMed ID: 27424313
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia.
Oh PC; Koh KK; Sakuma I; Lim S; Lee Y; Lee S; Lee K; Han SH; Shin EK
Int J Cardiol; 2014 Oct; 176(3):696-702. PubMed ID: 25147070
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
Koh KK; Han SH; Quon MJ; Yeal Ahn J; Shin EK
Diabetes Care; 2005 Jun; 28(6):1419-24. PubMed ID: 15920062
[TBL] [Abstract][Full Text] [Related]
5. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
7. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.
Capell WH; DeSouza CA; Poirier P; Bell ML; Stauffer BL; Weil KM; Hernandez TL; Eckel RH
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):307-13. PubMed ID: 12588776
[TBL] [Abstract][Full Text] [Related]
8. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
[TBL] [Abstract][Full Text] [Related]
9. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
10. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
Krysiak R; Gdula-Dymek A; Okopien B
Eur J Clin Pharmacol; 2011 Nov; 67(11):1109-17. PubMed ID: 21630032
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
12. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
13. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
14. Potential Effects of Omega-3 Fatty Acids on Insulin Resistance and Lipid Profile in Maintenance Hemodialysis Patients: a Randomized Placebo-Controlled Trial.
Gharekhani A; Dashti-Khavidaki S; Lessan-Pezeshki M; Khatami MR
Iran J Kidney Dis; 2016 Sep; 10(5):310-318. PubMed ID: 27721230
[TBL] [Abstract][Full Text] [Related]
15. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
Balasubramanyam A; Coraza I; Smith EO; Scott LW; Patel P; Iyer D; Taylor AA; Giordano TP; Sekhar RV; Clark P; Cuevas-Sanchez E; Kamble S; Ballantyne CM; Pownall HJ
J Clin Endocrinol Metab; 2011 Jul; 96(7):2236-47. PubMed ID: 21565796
[TBL] [Abstract][Full Text] [Related]
16. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
[TBL] [Abstract][Full Text] [Related]
17. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
[TBL] [Abstract][Full Text] [Related]
18. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
Anderlová K; Dolezalová R; Housová J; Bosanská L; Haluzíková D; Kremen J; Skrha J; Haluzík M
Physiol Res; 2007; 56(5):579-586. PubMed ID: 17184146
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
[TBL] [Abstract][Full Text] [Related]
20. Effects of omega-3 fatty acid supplementation on insulin metabolism and lipid profiles in gestational diabetes: Randomized, double-blind, placebo-controlled trial.
Samimi M; Jamilian M; Asemi Z; Esmaillzadeh A
Clin Nutr; 2015 Jun; 34(3):388-93. PubMed ID: 24973862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
